Secondary Logo

Journal Logo

May 2, 2003 - Volume 17 - Issue 7
pp: F11-F16,947-1117

Endogenous IL-7 is associated with increased thymic volume in adult HIV-infected patients under highly active antiretroviral therapy

Ruiz-Mateos, Ezequiel; de la Rosa, Rafael; Franco, Jaime M; More

AIDS. 17(7):947-954, May 2, 2003.


A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

van Leeuwen, Remko; Katlama, Christine; Murphy, Robert L; More

AIDS. 17(7):987-999, May 2, 2003.

Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal

Landman, Roland; Schiemann, Ricarda; Thiam, Safiatou; More

AIDS. 17(7):1017-1022, May 2, 2003.


Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients

Pérez-Olmeda, Mayte; Núñez, Marina; Romero, Miriam; More

AIDS. 17(7):1023-1028, May 2, 2003.


Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals

Brindeiro, Rodrigo M; Diaz, Ricardo S; Sabino, Ester C; More

AIDS. 17(7):1063-1069, May 2, 2003.

The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination

Duran, Ségolène; Peytavin, Gilles; Carrieri, Patrizia; More

AIDS. 17(7):1096-1099, May 2, 2003.

Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens

Trotta, Maria Paola; Ammassari, Adriana; Cozzi-Lepri, Alessandro; More

AIDS. 17(7):1099-1102, May 2, 2003.

High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors

Bossi, Philippe; Peytavin, Gilles; Lamotte, Claire; More

AIDS. 17(7):1108-1110, May 2, 2003.